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Introduction:  The  CLSI-M53-A,  Criteria  for Laboratory  Testing  and  Diagnosis  of Human  Immunodeﬁciency
Virus (HIV)  Infection;  Approved  Guideline  includes  an  algorithm  in which  samples  that  are reactive  on
a  4th  generation  EIA  screen  proceed  to a supplemental  assay  that  is  able  to  conﬁrm  and  differentiate
between  antibodies  to HIV-1  and  HIV-2.  The  recently  CE-marked  Bio-Rad  Geenius  HIV-1/2  Conﬁrmatory
Assay  was evaluated  as  an alternative  to the  FDA-approved  Bio-Rad  Multispot  HIV-1/HIV-2  Rapid  Test
which  has been  previously  validated  for use  in this  new  algorithm.
Methods:  This  study  used  reference  samples  submitted  to the  Canadian  – NLHRS  and  samples  from
commercial  sources.  Data  was  tabulated  in 2 × 2 tables  for statistical  analysis;  sensitivity,  speciﬁcity,
predictive  values,  kappa  and likelihood  ratios.
Results: The  overall  performance  of  the  Geenius  and  Multispot  was  very  high;  sensitivity  (100%,  100%),
speciﬁcity  (96.3%,  99.1%),  positive  (45.3,  181)  and  negative  (0, 0)  likelihood  ratios  respectively,  high  kappa
(0.96)  and  low  bias  index  (0.0068).  The  ability  to differentiate  HIV-1  (99.2%,  100%)  and HIV-2  (98.1%,  98.1%)
Ab was  also  very  high.
Conclusion:  The  Bio-Rad  Geenius  HIV-1/2  Conﬁrmatory  Assay  is  a  suitable  alternative  to  the  validated
Multispot  for  use  in  the  second  stage  of  CLSI M53  algorithm-I.  The  Geenius  has additional  features  includ-
ing  traceability  and  sample  and  cassette  barcoding  that  improve  the  quality  management/assurance  of
HIV testing.  It is  anticipated  that  the  CLSI  M53  guideline  and  assays  such  as  the Geenius  will reduce  the
number  of  indeterminate  test results  previously  associated  with  the  HIV-1  WB  and  improve  the  ability
to  differentiate  HIV-2  infection
Abbreviations: EIA, enzyme immunoassay; WB,  Western blot; IFA, immunoﬂuorescenc
iency  virus; Ab, antibody; Ag, antigen; NAT, nucleic acid testing; FDA, Food and Drug Adm
,  protein; DPP, Dual Path Platform; CE, European Conformity; NLHRS, National Laboratory
CS,  procedural control spot; k, kappa; PPV, positive predictive value; NPV, negative predi
revention; DNA, deoxyribonucleic acid; RNA, ribonucleic acid; APHL, Association of Pub
ND,  indeterminate; UNT, untypeable; CRF, circulating recombinant form; POS, positive; G
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. Introduction
Since 1989, HIV testing traditionally followed a two-step algo-
ithm in which a sample that tested repeatedly reactive on a screen
ssay such as the enzyme immunoassay (EIA) would then be con-
rmed in a second, or conﬁrmatory stage using a supplemental
est such as the Western blot (WB) or indirect immunoﬂuores-
ence assay (IFA) [1]. The recently published Clinical and Laboratory
tandards Institute (CLSI) guideline M53-A, Criteria for Laboratory
esting and Diagnosis of Human Immunodeﬁciency Virus (HIV) Infec-
ion; Approved Guideline contains an algorithm-I which places an
mphasis on identifying acute/early infections ﬁrst and then iden-
ifying and differentiating HIV-1 and HIV-2 (Fig. 1) [2,3]. To do this,
lgorithm-I includes three categories of HIV testing technologies; a
i) 4th generation HIV antibody (Ab) and antigen (Ag) combo assay,
ii) HIV-1/HIV-2 differentiation assay and (iii) Nucleic acid test-
ng (NAT). The new algorithm utilizes the latest serological tests
o identify HIV and excludes the HIV-1 Western blot (WB), which
as been the traditional conﬁrmatory test for serological conﬁrma-
ion but has not advanced in sophistication since being introduced
n the 1980s. This new algorithm, (speciﬁcally the second stage)
ddresses the need to detect and differentiate HIV-2 from HIV-1
b. The FDA-approved Bio-Rad Multispot HIV-1/HIV-2 has previ-
usly been validated for this purpose (Fig. 2). The Multispot is a
ingle use ﬂow-through rapid test that can detect and differenti-
te between HIV-1 and HIV-2 in serum or plasma. There are four
pots on each test cartridge; a procedural control, HIV-1 (r-gp41),
IV-1 (sp-gp41) and HIV-2 (sp-gp36). The Multispot has been FDA
pproved since November, 2004. The Bio-Rad Geenius HIV-1/2 Con-
rmatory Assay is a new test which may  serve a similar function
s the previously validated Multispot (Fig. 2). The Geenius is a sin-
le use test for the conﬁrmation and differentiation of HIV-1 and
IV-2 Ab in several sample types including whole blood, serum or
(i) HIV-1/HIV-2
Ag/Ab
Immunoa ssay
(ii) HI V-1/HIV-2
Ab Diﬀerenaon
Immunoa ssay
(iii) Nu cleic
Acid Te sng
HIV-1/HI V-2
Ag/Ab
Immunoas say
Negave for
HIV-1/HI V-2
Ab and p24 Ag
Reacve
Repeat in
Duplicate
(-/-)
Negave for
HIV-1/HI V-2
Ab and p24 Ag
(+
HIV
Diﬀ
Im 
HIV-1(+) HIV-2(-)
Posive for HIV-1 Ab
HIV-1(-) HIV-2
Posive for HIV-
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plasma. In this test, recombinant or synthetic peptides speciﬁc for
HIV-1 (gp160, gp41, p31, p24) or HIV-2 (gp140, gp36) are applied as
discrete lines within a plastic cassette. The cassette employs Dual
Path Platform (DPP)TM technology (Chembio) in which Ab binds
the appropriate Ag before detection reagents are added to visual-
ize the test result [4]. The Geenius assay has been CE-marked since
February, 2013 but is not approved elsewhere including Canada
and the United States.
This study performed a comparative evaluation of the new
(CE-marked) Bio-Rad Geenius HIV 1/2 Conﬁrmatory Assay as an
alternative to the (FDA-approved) Bio-Rad Multispot HIV-1/HIV-2
Rapid Test using a range of sample types including those submit-
ted to the Canadian National Laboratory for HIV Reference Services
(NLHRS).
2. Methods
2.1. Samples
Two sets of samples were used to analyze assay performance;
two-hundred and eighty-nine (n = 289; 181-positive (HIV-1, 128;
HIV-2, 53), 108 negative) well pedigreed NLHRS samples which
represent the ‘reference standard’ (resulting from a combination
of the NLHRS testing algorithm and clinical follow-up) and spe-
ciality samples including seroconversion (commercial and clinical),
low reactive, HIV-2 and world subtype samples containing HIV-
1 non-B subtypes. All positive samples were initially EIA (3rd or
4th generation) reactive and conﬁrmed by serological and or PCR.
All negative samples were screened as nonreactive by EIA (3rd/+) or (+/-)
-1/HIV-2 Ab
erenaon
munoassay
(+)
2 Ab
HIV-1(+) HIV-2(+)
Posive for HIV Ab HIV-1(-) HIV-2(-)
NAT
Posive
for HIV-1
RNA
Negave
for HIV-1
RNA
ds Institute M53-A algorithm-I.
or 4th generation). Based on an expected sensitivity and speci-
ﬁcity of 99.5% with a 95% conﬁdence interval (CI) and precision
of ±5%, and prevalence of 0.3% in Canada, the number of sam-
ples used to measure sensitivity (positive) and speciﬁcity (negative)
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Overall sensitivity for both the Geenius and Multispot assaysig. 2. (a) Bio-Rad Multispot HIV-1/HIV-2 Rapid Test (Images kindly provided by Bio-R
espectively exceeded the minimum number of samples required
5].
.2. Bio-Rad Geenius HIV-1/2 Conﬁrmatory Assay [6]
The cassette is read by an automated reader utilizing a pro-
rietary algorithm with four interpretative criteria available. Test
esults and interpretations include; (a) negative – only the control
ine shows color (pink/purple) development, (b) HIV-1 positive –
he control line and any two of the four HIV-1 test lines with at
east one being env, (c) HIV-2 positive – the control line and both
IV-2 bands, (d) indeterminate – if the control line and any other
ombination that does not satisfy the criteria for positivity and (e)
nvalid – any other result in which the control line has not devel-
ped. The results obtained for both the HIV-1 and HIV-2 results are
hen analyzed by a GLOBAL HIV-1/HIV-2 Interpretation criteria to
enerate ﬁnal results; (i) HIV-1 indeterminate or positive, (ii) HIV-2
ndeterminate or positive, or (iii) HIV negative, indeterminate, pos-
tive, or untypeable. For the purpose of consistency we  have used
he term untypeable to refer to any sample that satisﬁed the crite-
ia for HIV positivity but was unable to be differentiated between
IV-1 or HIV-2. A visual record and ﬁnal interpretation is stored
lectronically allowing for full traceability of both the sample and
est cassette. The overall time to perform the assay is 30 min  per
ample..3. Bio-Rad Multispot HIV-1/HIV-2 Rapid Test [7]
The procedure was carried out following the kit instructions
rom the manufacturer with the ﬁnal result and interpretationb) Bio-Rad Geenius HIV-1/2 Conﬁrmatory Assay (Images kindly provided by Bio-Rad).
based on visual reading. Test results and interpretation include; (a)
nonreactive – only the procedural control spot (PCS) shows color
(purple) development, (b) HIV-1 reactive – the PCS and either or
both of the HIV-1 spots have developed, (c) HIV-2 reactive – the
PCS and the HIV-2 spot have developed, (d) HIV reactive but undif-
ferentiated – the PCS, the HIV-2 spot and one or both of the HIV-1
spots have developed and (e) invalid – any other result in which
the PCS has not developed. The overall time to perform the assay is
approximately 15 min  per sample.
2.4. Statistical analysis
Data based on 289 samples was tabulated in standard 2 × 2
table format for analysis of (i) sensitivity and speciﬁcity, (ii) pre-
dictive values (positive and negative) plotted as a function of
prevalence, (iii) kappa (k) statistic to assess rater agreement and
(iv) likelihood ratios (positive and negative). McNemar’s test for sig-
niﬁcance was  used to account for paired-data on the same sample
set.
3. Results
3.1. Assay performance (Tables 1a–1c)was 100%. Speciﬁcity for Multispot (99.1%) was  slightly higher than
the Geenius (96.3%). This difference was not statistically signiﬁcant
(p = 0.688). The agreement between the two assays was  very high
(k = 0.96 [0.92–0.99]).
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Table  1a
Bio-Rad Geenius 2 × 2 table.
n = 289 True result
Positive Negative
Positive 181 4
Negative 0 104
Table 1b
Bio-Rad Multispot 2 × 2 table.
n = 289 True result
Positive Negative
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NPositive 181 1
Negative 0 107
.2. Ability to differentiate HIV-1 and HIV-2 samples (Fig. 3)
HIV-1 samples (n = 128): The Geenius had a differentiation rate of
9.2% with one untypeable sample observed. Initially the Multispot
ad a differentiation rate of 97.7% with three untypeable samples
bserved. Upon a 1/10 dilution these samples were differentiated as
IV-1 giving a new rate of 100%. This difference was not signiﬁcant
p = 0.128). None of the untypeable samples were common to both
ssays..
HIV-2 samples (n = 53): Both the Geenius and Multispot had a
ifferentiation rate of 98.1% with one (common) untypeable sample
bserved for each assay.
.3. Other sample types (Supplementary Material S1)
Very few differences were observed between the Geenius and
ultispot on a variety of other sample types including serocon-
ersion series, HIV-1 non-B subtypes, low titer and other reference
amples.
. Discussion
.1. Overall performanceTables 1a–1c and Fig. 3 summarize the performance and
dditional features. Utilizing HIV-1, HIV-2 and negative samples
btained from a national HIV reference testing lab the Geenius
able 1c
ummary of performance and features of the Bio-Rad Geenius and Bio-Rad Multispot.
Diagnostic performance
Sensitivitya [95% CI] 
Speciﬁcityb [95% CI] 
Positive predictive value 
Negative predictive value 
Likelihood ratio (w) pos 
Likelihood ratio (w) neg 
Kappa (k) 
Bias index 
Quality  management
Interpretation of test result 
Time  
Number of steps 
Sample pre-dilution step 
Procedural control 
Test  result storage 
Traceability 
, weighted for prevalence.
a Sensitivity was  based on the ability to identify an HIV Ab positive sample as either HI
b Speciﬁcity was  based on the ability to identify an HIV Ab negative sample as either H
c Can be modiﬁed to four different user preferences including manual.
ote:  Any sample identiﬁed as indeterminate or untypeable was  included in the positive Virology 58S (2013) e85– e91
and Multispot had very high values reported for both sensitiv-
ity (Geenius/Multispot, 100%/100%) and speciﬁcity (96.3%/99.1%).
The speciﬁcity was not as high as claimed in the manufacturer’s
kit inserts or the two  external (poster) presentations by the
manufacturer which reported a minimum speciﬁcity of 99.9%.
However, it should be noted that this study included reference
samples submitted from Canadian public health labs and are there-
fore representative of the ‘intended’ or ‘target’ population. The
method of validation employed by the manufacturer for licens-
ing approval may  not have used samples normally associated
with the target population which could explain the discordance
between the results obtained here [6–9]. However, in our expe-
rience as a national reference lab, it is rare for us to observe
the extremely high sensitivities and speciﬁcities often reported
by manufacturers when verifying kit performance. Interestingly,
although a high kappa is usually associated with a high bias index,
in this evaluation even with a high k-value (0.96), we observed a
very low bias index (0.0068) indicating that agreement (between
the Geenius and Multispot) was  unlikely to be inﬂuenced by
bias.
In low prevalence populations like in Canada, the effect of lower
speciﬁcity is always reﬂected in a low positive predictive value
(PPV) (Fig. 4). The positive predictive value of both the Geenius
(7.5%) and Multispot (25%) are predictably low based on an average
prevalence of 0.3% (Canada). We  should note that the speciﬁci-
ties and calculated PPV observed may  be somewhat misleading
as the assay would not be used as a single test. As the intended
use of the Geenius and the Multispot would be in a multi-stage
algorithm, it is possible that ‘false-reactive’ samples on these two
supplemental assays would have been detected as negative at the
initial screening stage (likely on a 4th generation combo assay)
thereby never reaching the supplemental testing stage. Further
veriﬁcation studies by other labs including samples representa-
tive from the intended or target population and data generated
after incorporation in a real-world diagnostic setting are warranted
and would provide additional data on performance and the algo-
rithm.
Regarding the ability to differentiate HIV-1 samples, the Mul-
tispot was  100% (128/128) and the Geenius was  99.2% (127/128).
The differentiation rate of both assays to identify true HIV-2 sam-
ples was  identical (98.1%, 52/53). Although our ‘overall’ sensitivity
was identical (100%, Tables 1a–1c), when analyzing HIV-1 and
HIV-2 samples speciﬁcally, our analysis showed the Multispot
Bio-Rad Geenius Bio-Rad Multispot
100% 100%
96.3% [90.2–98.8] 99.1% [94.2–99.9]
7.5% 25%
100% 100%
45.3 [17.2–119] 181 [25.6–1278]
0 0
0.96 (0.92–0.99)
0.0068
Automatedc Manual
∼30 min  ∼15 min
3 >10
No Yes
Yes Yes
Automated – electronic Manual
Yes (automated) No (manual)
V-1 Ab or HIV-2 Ab positive.
IV-1 Ab or HIV-2 Ab negative.
tally during 2 × 2 table analysis.
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HIV-2 Sampl es 
(n=53) 
HIV-1 Sampl es 
(n=128) 
100%80%60%40%20%0%
Mulspot ³
Geenius ³
Mulspot ²
Geeniu s ¹ 99.2%   (127/1 28)
100%   (128/128)
98.1%   (52 /53 )
98.1%   (52/53)
Fig. 3. Differentiation of HIV-1 and HIV-2 samples.4 1One untypeable sample. 2Three untypeable samples pre-dilution (97.7%; 125/128), after a 1/10 dilution all were HIV-1
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Fb  positive. 3One untypeable sample. 4Differentiation was  based in the ability to
espectively.
ppeared better at differentiating HIV-1 from HIV-2 (100% vs.
9.2%) samples although this was not considered signiﬁcant
p = 0.128).
.2. HIV-2 diagnosis
The ability to differentiate HIV-2, are of great importance and
ighlight the strength of the CLSI M53  guideline which no longer
ecommends the HIV-1 WB which has not evolved since its intro-
uction during the 1980s. In addition to the WB  being unable to
ifferentiate HIV-2 Ab, the literature is replete with reports of the
oor speciﬁcity that has been associated with the WB.  Although
revalence is low in North America, the inability to detect and dif-
erentiate HIV-2 has implications epidemiologically as well as in
he clinical treatment and follow-up of those infected [10]. This
as in large part been due to the lack of approved tests. While
he majority of HIV screening assays contain antigens allowing
or the ability to detect HIV-2 (and HIV-1) Ab during screening,
here are no approved assays for the differentiation between
IV-2 and HIV-1 Ab at the conﬁrmatory stage. Cross reactivity on
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ig. 4. Positive and negative predictive values for the Geenius and Multispot assays in popify known HIV-1 or HIV-2 Ab containing samples as HIV-1 or HIV-2 Ab positive
the traditional HIV-1 WB  may  lead to either an ‘indeterminate’
result requiring additional testing or it may  lead to a false diagnosis
of HIV-1 positivity as has been previously reported [11,12]. Further-
more, the absence of cross reactivity of an HIV-2 Ab positive sample
on the HIV-1 WB can occur, resulting in a false-negative ﬁnal result
(internal validation-NLHRS). In the United States there is currently
one FDA approved assay, the Bio-Rad HIV-1/2 Multispot Rapid Test,
which has the ability to differentiate between HIV-1 and HIV-2 Ab.
As a national reference lab, the NLHRS has used the CE-marked
Innogenetics Inno-LIA HIV-I/II Score assay since 2002 which has the
ability to detect and differentiate HIV-2 Ab. Formal epidemiological
studies using a combination of HIV-1/2 differentiation assays and
retrospective analysis of HIV-1 WB patterns, similar to the study
conducted recently by the CDC are warranted here in Canada [12].
The Inno-LIA HIV assay has also dramatically reduced the num-
ber of ‘indeterminate’ samples normally associated with the HIV-1
WB (NLHRS in-house testing). We  also utilize an in-house HIV-2
speciﬁc PCR (DNA and RNA) leading to a comprehensive ability to
detect and differentiate HIV-2 and HIV-1 at both the serological and
molecular level.
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Multispot EIA with Western blot for conﬁrmatory diagnosis of HIV. J Clin Virol
2011;52(December (Suppl.)):S41–4.
[12] Torian LV, Selik RM,  Branson B, Owen M,  Granade T, Shouse L, et al. HIV-290 L. Malloch et al. / Journal of Cl
.3. Quality management
In a laboratory with a quality management system, the
eenius has several advantageous features over the Multispot
Tables 1a–1c). The Geenius assay employs proprietary algorithms
oupled with an automated reader reducing subjectivity between
ab personnel. The assay still allows a total of four different modes
f interpretation allowing for ﬂexibility. The automated reader also
equires scheduled maintenance which if not implemented will
ender the reader non-operational. The traceability features within
he Geenius allow for the barcoding of both the sample and cas-
ette along with digital capture and storage of the image observed
n the cassette. Reporting, collation and ﬁnal sign off are readily
menable with different levels of security available. In addition to
he absence of a sample pre-dilution step and in light of its similar
erformance to the Multispot, the Geenius is an assay that poten-
ially satisﬁes the second stage of the CLSI M53  guideline and likely
rovides a superb advantage over the HIV-1 WB.  One weakness of
his study is that it did not include the WB assay which is the current
gold’ standard for HIV conﬁrmatory testing. However considering
he validation data that has since occurred since the publication of
he CLSI M53  guideline we felt that it was not necessary to include
his test during this evaluation [10,13,14].
. Conclusion
Changes to the original 1989 guidelines which relied heavily
n the HIV-1 WB  were long overdue and the publication of the
LSI M53-A HIV testing guideline represents a signiﬁcant improve-
ent. The latest technology offered by the 4th generation assay and
AT shortens the window period of HIV detection and their incor-
oration into the algorithm allows laboratories to better detect
cute phase infections (pre-seroconverters) and differentiate HIV-
 (from HIV-1) during the conﬁrmatory stage of testing. In addition
o differentiating HIV-2, supplemental HIV-1/HIV-2 assays, such as
he Geenius and Multispot will have the added beneﬁt of reducing
he number of indeterminate ﬁnal test results that have plagued the
IV-1 WB.  Although beyond the scope of this paper, this is likely
ue to test design and the use of synthetic and recombinant anti-
ens (Geenius and Multispot) versus the whole viral lysate based
IV-1 WB.
A recent APHL survey of the effect of the M53  guideline identi-
ed increased cost as a concern of implementing new tests such as
he HIV-1/HIV-2 differentiation assay [15]. Economic evaluations
imilar to the one reported at the CDC HIV Diagnostic Meeting
December 2012) highlighted the cost effectiveness of the algo-
ithm’s ability to identify newly acquired (acute) infection. This
ould be helpful in evaluating the cost-effectiveness of using
ssays like the Geenius and Multispot, on HIV-1 negative sam-
les and differentiating HIV-2 samples to replace the WB  [16]. As
tated earlier it would not be surprising if this ﬁgure was  signiﬁ-
ant. Another major issue raised regarding the implementation of
n HIV-1/HIV-2 differentiation assay and replacement of the HIV-1
B has been the absence of a formal recommendation from the
DC which is a requirement in several state public health testing
abs [15]. In conclusion, the Bio-Rad Geenius represents an alter-
ative to the Bio-Rad Multispot and includes additional features
hat should improve and enhance the overall quality manage-
ent of the M53  algorithm in laboratories implementing this new
ssay.ote to reader
Since the submission of the original manuscript, Bio-Rad
eceived FDA approval for modiﬁcation of its package insert for
[Virology 58S (2013) e85– e91
the Multispot assay to include interpretative criteria for use as a
(supplemental) antibody differentiation test in a diagnostic algo-
rithm such as the one proposed in CLSI M53. This new criteria
makes the Multispot unique in being able to be used as
either a screening or supplemental (conﬁrmatory) assay for HIV
antibody.
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